Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04234997 · ClinicalTrials.gov registry record · Phase 2
Suvorexant to Reduce Symptoms of Nicotine Use
A Phase 2 study of Smoking Cessation, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT04234997 is a Phase 2 study of Smoking Cessation that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 14 participants, below the 475-participant average among 188 other Smoking Cessation trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04234997, a Phase 2 study of Smoking Cessation, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the impact of suvorexant on established measures of smoking relapse risk (craving,withdrawal, stress reactivity, latency to self-administration) and to validate the somnolent effect of suvorexant on sleep metrics in a sample of individuals with tobacco use disorder
Conditions Studied
Interventions
- DRUG Suvorexant 20 mg
- DRUG Suvorexant 0mg
Study Locations (1)
Texas
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-08-23 |
| Est. Completion | 2024-08-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04234997
The ClinicalTrials.gov registry entry for NCT04234997 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 475-participant average among 188 other Smoking Cessation trials with a reported enrollment target (97% lower). The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which Suvorexant 20 mg is the first listed.
NCT04234997 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04234997 about?
NCT04234997 is a clinical study titled "Suvorexant to Reduce Symptoms of Nicotine Use". The purpose of this study is to assess the impact of suvorexant on established measures of smoking relapse risk (craving,withdrawal, stress reactivity, latency to self-administration) and to validate the somnolent effect of suvorexant on sleep metrics in a sample of individuals with tobacco use diso...
What is the current status of trial NCT04234997?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2021-08-23. Estimated completion is 2024-08-22.
What conditions does trial NCT04234997 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT04234997?
The interventions under investigation include: Suvorexant 20 mg (DRUG), Suvorexant 0mg (DRUG).
Who is sponsoring clinical trial NCT04234997?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04234997 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
RECRUITING · Phase 2
-
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
RECRUITING · Phase 2
-
Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate
COMPLETED · Phase 2
-
Treating Smokers With Mental Illness
COMPLETED · Phase 2
-
Pharmacogenetics, Emotional Reactivity and Smoking
COMPLETED · Phase 2
-
Provoked Craving Relief Study by NRT
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.